AbbVie Inc. (ABBV) announced Wednesday that Health Canada approved Qulipta, also known as atogepant, for preventing migraines in adults with at least four migraine days per month. The approval was based on a Phase 3 PROGRESS trial that showed a significant reduction in monthly migraine days with Qulipta 60 mg once daily for adult patients with chronic migraine.

AbbVie Inc.（ABBV）周三宣布，加拿大卫生部批准Qulipta（也称为atogepant）用于预防每月至少有四天偏头痛的成年人的偏头痛。该批准是基于一项3期PROGRESS试验，该试验显示，对于成年慢性偏头痛患者，每天一次服用60毫克曲利普塔可显着减少每月偏头痛天数。

The company stated that Qulipta is the first oral, small-molecule CGRP receptor antagonist approved for both episodic and chronic migraine prevention and is available in three strengths - 10 mg, 30 mg, and 60 mg. For comments and feedback contact: editorial@rttnews.comBusiness News.

该公司表示，Qulipta是第一种被批准用于发作性和慢性偏头痛预防的口服小分子CGRP受体拮抗剂，有三种强度-10 mg，30 mg和60 mg。有关评论和反馈，请联系：editorial@rttnews.comBusiness新闻。